Smart Strategies for the Beginning and End of Drug Development

August 23, 2017

To maximize the benefits of streamlined development, whenever possible, companies should consider mitigating risk by utilizing targeted strategies. In the beginning, that may mean engaging with the FDA on biomarkers. At the end, managed access programs (MAPs) can help companies deliver products ethically to the patients who need them, gather real world evidence for payers and providers, and even achieve an earlier return on investment (ROI).

Previous Flipbook
FDA's Accelerated Pathways Are The New Normal
FDA's Accelerated Pathways Are The New Normal

Accelerated Pathways work if you work with them -- learn how.

Next Flipbook
Early Stage Haste Creates Future Waste: Three Strategies that Integrate Your Value Story
Early Stage Haste Creates Future Waste: Three Strategies that Integrate Your Value Story

Integrating clinical and regulatory functions from an early stage adds value to your product, reduces costs...